TA33.Combo treatment increased the colocalization between transcripts associated with cancer cell identity (e.g., S100a6, Klf4, Anxa2, Cdkn2a) and transcripts related to antigen presentation (e.g., Ciita, H2-Dmb1), T cell identity (e.g., Trac) and T cell activation (e.g., Sell, Il2rb, Il12rb1) compared to TA33 treatment (Fig. 6F, supplementary Fig. 14C, D, Supplementary data 6). The gene discussed is ANXA2; the disease is cancer.